AMRN Amarin Corp

    RNS Number : 0903V
  Amarin Corporation Plc
  22 May 2008
   




    AMARIN ANNOUNCES COMPLETION OF THE FIRST TRANCHE OF $60 MILLION PRIVATE PLACEMENT 

    Appoints Four New Directors to Board

    DUBLIN, Ireland, May 22, 2008 - Amarin Corporation plc (NASDAQ: AMRN) today announced that it has closed the $30 million first tranche
of its previously announced $60 million private placement. The net proceeds of the first tranche, after deducting the placement agents' fees
and estimated offering expenses, will be approximately $27 million. 

    In conjunction with the financing, Amarin has appointed to its Board representatives of the four largest investors in the placement. The
new non-executive directors are Dr. James Healy of Sofinnova Ventures, Dr. Carl Gordon of OrbiMed Advisors LLC, Dr. Eric Aguiar of Thomas,
McNerney & Partners, and Dr. Srinivas Akkaraju of Panorama Capital. Non-executive directors retiring from the Amarin Board are Mr. John
Groom, Dr. Simon Kukes, Dr. Prem Lachman, Professor William Hall, and Dr. Michael Walsh. 

    Thomas Lynch, Chairman and Chief Executive Officer of Amarin, commented "I am pleased to welcome our new board members and look forward
to working closely with them in growing our company in the future. On behalf of the Company's directors and my colleagues at Amarin, I would
also like to thank our retiring non-executive directors for their valuable contribution to Amarin over the past number of years." 

    Incoming director Dr. Healy, General Partner of Sofinnova Ventures, added "We are excited to be involved with Amarin at this juncture,
in what we view as a new phase in the Company's development. The combination of Amarin's experienced management team, lipid science
expertise and promising pipeline make this an attractive opportunity."

    The Company is also decreasing the size of its Board from eleven members to eight members, to better reflect its stage of development.
As a result, Mr. Alan Cooke and Dr. Declan Doogan have also retired from the Board. Mr. Cooke's and Dr. Doogan's executive roles as
President and Chief Operating Officer and Head of Research and Development, respectively, are unchanged.

    Following the closing of this first tranche of the financing, Amarin has 27,046,716 Ordinary Shares in issue. Cowen and Company LLC
acted as the lead placement agent for the transaction, with Rodman & Renshaw LLC acting as co-placement agent.

    Amarin's Board now comprises Mr. Thomas Lynch, Chairman and Chief Executive Officer; Dr. William Mason, Lead Independent Director; Dr.
John Climax; Mr. Anthony Russell-Roberts; Dr. James Healy; Dr. Carl Gordon; Dr. Eric Aguiar and Dr. Srinivas Akkaraju.

    Short biographies of the new directors follow:

    James Healy, M.D., Ph.D., joined Sofinnova Ventures as a General Partner in 2000. Dr. Healy was a founding investor and board member of
Cellective (acquired by MedImmune), CoTherix (acquired by Actelion), Novacea, and Intermune. He also serves on the boards of directors of
several private companies. In the pharmaceutical industry Dr. Healy held positions at Bayer Pharmaceuticals (Miles) and ISTA Pharmaceuticals
prior to its initial public offering. He began his private equity career at Sanderling. Dr. Healy earned B.A.s in Molecular Biology and
Scandinavian Studies from the University of California at Berkeley, where he graduated with Distinction in General Scholarship, Honors, and
received a Departmental Citation. He received his M.D. from Stanford University's School of Medicine through the Medical Scientist Training
Program, and earned his Ph.D. in Immunology from Stanford University, where he was a Beckman Scholar and received a bursary award from the
Novartis Foundation. Dr. Healy teaches a course on entrepreneurship at Stanford University, and is an active member of the BIO-NVCA Working Group.


    Carl L. Gordon, Ph. D., CFA, is a founding General Partner and Co-Head of Private Equity of OrbiMed Advisors LLC. Dr. Gordon is active
in both private equity and small-capitalization public equity investments. He was a senior biotechnology analyst at Mehta and Isaly from
1995 to 1997. He was a Fellow at The Rockefeller University from 1993 to 1995. Dr. Gordon received a Ph.D. in Molecular Biology from the
Massachusetts Institute of Technology. His doctoral work involved studies of protein folding and assembly. He received a Bachelors degree
from Harvard College.

    Dr. Eric Aguiar is a Partner at Thomas, McNerney & Partners. He has 16 years of experience in the biopharmaceutical industry. From 2001
to 2007 he was a Managing Director at HealthCare Ventures. Prior to joining HealthCare Ventures, he was CEO of Genovo, Inc.  Dr. Aguiar was
an executive at TheraTech, a drug delivery company that was sold to Watson Pharmaceuticals in 1997. He was a Managing Director and Vice
President of Philadelphia Ventures in the mid-1990's. Prior board seats have included CardioKine, SkinMedica, Vaxinnate, Metaphore
Pharmaceuticals, 3-D Pharmaceuticals, and ThromboSys. He graduated from Harvard Medical School and Cornell University with honors.

    Dr. Srinivas Akkaraju is a founding Managing Director of Panorama Capital and focuses primarily on life sciences investments.
Previously, he was with J.P. Morgan Partners, serving as a Principal, starting in April 2001 and becoming a Partner in January 2005. From
1998 to 2001, Dr. Akkaraju was in Business and Corporate Development at Genentech, Inc., most recently as Senior Manager responsible for
worldwide partnering activities, in-licensing of therapeutics, and out-licensing of development projects. In addition to his business
development role, Dr. Akkaraju also served as a Project Team Leader for one of Genentech's clinical development products. During this time,
he also was a founding member of BioStreet, an online marketplace for biotech opportunities. Dr. Akkaraju holds B.A. degrees in both
Biochemistry and Computer Science from Rice University and an M.D. and Ph.D. in Immunology from Stanford University School of Medicine. Dr.
Akkaraju currently serves on the board of directors of Presidio Pharmaceuticals, Itero Biopharmaceuticals, Barrier Therapeutics, Inc., Phenomix Corporation, Piramed Limited, Seattle Genetics, Inc., and Pharmos,
Inc.

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be the sale of the
securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the
securities laws of any such state. 

    About Amarin
    Amarin is a biopharmaceutical company focused on improving the lives of patients suffering from cardiovascular and central nervous
system (CNS) diseases. Amarin's cardiovascular programs capitalize on the known therapeutic benefits of essential fatty acids in
cardiovascular disease. Amarin's CNS development pipeline includes programs in myasthenia gravis, Huntington's disease, Parkinson's disease,
epilepsy and memory. Amarin also has two proprietary technology platforms: a lipid-based technology platform for the targeted transport of
molecules through the liver and/or to the brain, and a unique mRNA technology based on cholinergic neuromodulation. Amarin has its primary
stock market listing in the U.S. on the NASDAQ Capital Market ("AMRN").

    Contacts: 
    Amarin +353 (0)1 669 9020 
    Thomas Lynch, Chairman and Chief Executive Officer
    Alan Cooke, President and Chief Operating Officer
    Darren Cunningham, EVP Strategic Development and Investor Relations
    investor.relations@amarincorp.com 

    Investors: 
    Lippert/Heilshorn & Associates, Inc. 
    Anne Marie Fields +1 212 838 3777
    Bruce Voss +1 310 691 7100 

    Media: 
    Powerscourt +44 (0) 207 250 1446 
    Rory Godson 
    Paul Durman 

    Disclosure Notice 
    The information contained in this document is as of May 22, 2008. Amarin assumes no obligation to update any forward-looking statements
contained in this document as a result of new information or future events or developments. This document contains forward-looking
statements about Amarin's financial condition, results of operations, business prospects and products in research that involve substantial
risks and uncertainties. You can identify these statements by the fact that they use words such as "will", "anticipate", "estimate",
"expect", "project", "forecast", "intend", "plan", "believe" and other words and terms of similar meaning in connection with any discussion
of future operating or financial performance or events. Among the factors that could cause actual results to differ materially from those
described or projected herein are the following: Amarin's ability to maintain sufficient cash and other liquid resources to meet its
operating and debt service requirements; the success of Amarin's research and development activities; decisions by regulatory authorities regarding whether and when to approve Amarin's drug applications, as
well as their decisions regarding labeling and other matters that could affect the commercial potential of Amarin's products; the speed with
which regulatory authorizations, pricing approvals and product launches may be achieved; the success with which developed products may be
commercialized; competitive developments affecting Amarin's products under development; the effect of possible domestic and foreign
legislation or regulatory action affecting, among other things, pharmaceutical pricing and reimbursement, including under Medicaid and
Medicare in the United States, and involuntary approval of prescription medicines for over-the-counter use; Amarin's ability to protect its
patents and other intellectual property; claims and concerns that may arise regarding the safety or efficacy of Amarin's product candidates;
governmental laws and regulations affecting Amarin's operations, including those affecting taxation; risks relating to the Company's ability to maintain its Nasdaq listing; general changes in
International Financial Reporting Standards; and growth in costs and expenses. A further list and description of these risks, uncertainties
and other matters can be found in Amarin's Form 20-F for the fiscal year ended December 31, 2007, filed with the SEC on May 19, 2008.

    ž ž ž



    

This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
BOABDGDUBUDGGID

Amarin (LSE:AMRN)
Historical Stock Chart
From Apr 2024 to May 2024

Amarin (LSE:AMRN)
Historical Stock Chart
From May 2023 to May 2024